Skip to search formSkip to main contentSkip to account menu

Fazaclo

Known as: CLOZAPINE (FAZACLO) 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2019
2019
2012
2012
  • 2012
  • Corpus ID: 20426481
BECAUSE OF A SIGNIFICANT RISK OF AGRANULOCYTOSIS, A POTENTIALLY LIFE-THREATENING ADVERSE EVENT, CLOZAPINE SHOULD BE RESERVED FOR… 
2012
2012
OBJECTIVE To compare the prevalence of obsessive-compulsive symptoms (OCS) in a population of patients with schizophrenia taking… 
2008
2008
AbstractBackground: This study compared the bioequivalence of FazaClo® (clozapine orally disintegrating tablets) 100 mg to… 
Review
2007
Review
2007
  • R. Ganguli
  • Journal of Clinical Psychiatry
  • 2007
  • Corpus ID: 24009514
Compared with the general population, individuals with schizophrenia demonstrate an increased prevalence of obesity. While most… 
2007
2007
OBJECTIVE Interventions improving adherence to antipsychotic medication are needed. The present study examined the effects on… 
Highly Cited
2006
Highly Cited
2006
BACKGROUND The main objective was to assess the efficacy of a weight management program designed for outpatients taking… 
Review
2005
Review
2005
Patients with schizophrenia are at significantly increased risk for infection with human immunodeficiency virus (HIV), hepatitis…